Individuals
Businesses
Company
Intelligence
News
African Capital Markets
EnglishEnglish
share on twittershare on linkedinshare on facebookshare to whatsapp
share on mail
share on instagram

IFC backs Biovac with $7m to expand vaccine manufacturing in Africa

Daba Finance/IFC backs Biovac with $7m
AFRICAN STOCKS AND FINANCEDecember 18, 2023 at 10:26 PM UTC

The International Finance Corporation (IFC) has invested in Biovac, a prominent biopharmaceutical company in South Africa. The $7 million equivalent loan from the corporation will aid Biovac in expanding its existing production of various vaccines, including those for HPV, meningococcal disease, cholera, and pediatric vaccines.

Additionally, IFC and Biovac have entered into a collaboration agreement to offer project development support for Biovac's plans to construct a new multi-vaccine production plant in Cape Town. The new facility is expected to significantly increase Biovac's production capacity from the current 150 million doses to around 560 million vaccine doses annually.

The financing and collaboration with IFC will also facilitate Biovac's development of local capabilities for manufacturing traditional bacterial-based vaccines and messenger RNA (mRNA)–based vaccines. This initiative aims to strengthen African vaccine value chains and reduce the continent's reliance on vaccine imports, contributing to increased vaccine production and pandemic preparedness in Africa.

Key Takeaways

At the outset of the recent global pandemic, Africa, like other poorer regions, was left without adequate vaccine supplies, highlighting the need to develop its production. The continent imports more than 70% of all the medicines it needs, gulping $14 billion per year. Bolstering local capacity should serve as a major boost to the health prospects of a region that has been battered for decades by the burden of several diseases and pandemics such as Covid-19, but with very limited capacity to produce its medicines and vaccines. Biovac is one of the few vaccine companies in Africa with product development capabilities. It reportedly supplies about 80% of South Africa's routine pediatric vaccines and since 2003 has delivered over 450 million vaccine doses to public hospitals, clinics, and depots in South Africa, Angola, Botswana, Eswatini, Lesotho, Mozambique, and Namibia.

IFC
Vaccine
Biovac
mRNA
South Africa
Finance
Investments
Healthcare

Think someone else should see this?

share on twittershare on linkedinshare on facebookshare to whatsapp
share on mail
share on instagram
Stay informed with our newsletters read by 25,000+ professionals worldwide
Newsletter companiesNewsletter companiesNewsletter companiesNewsletter companiesNewsletter companiesNewsletter companies

Next Frontier

Stay up to date on major news and events in African markets. Delivered weekly.

Pulse54

UDeep-dives into what’s old and new in Africa’s investment landscape. Delivered twice monthly.

Events

Sign up to stay informed about our regular webinars, product launches, and exhibitions.

+25k investors have already subscribed

To invest in this opportunity and other opportunities across Africa

Download the daba finance app on your mobile through
appstore iconappstore icon
Phone Image

Take action.

Download app

Start investing in Africa’s best opportunities, including stocks, bonds, startups, venture funds, and more.

Partner with us

Unlock exciting business opportunities and growth potential.

Join Daba

Become a part of our vibrant community and enjoy exclusive benefits.

Contact us

Reach out to us for inquiries, support, or collaboration.
For Investor
StrategiesPortfolio ManagementAfrican Capital MarketsNews
Daba Pro Intelligence
For Capital Seekers
For StartupsFor Fund ManagersFor Private CompaniesFor Lenders
For Partners
Commercial BanksBroker DealersAsset ManagersInvestment BanksInvestment Advisors and ConsultantsLenders and Microfinance
Company
About UsMarket UpdatesEventsBlog and PodcastNewsletterCase StudiesAffiliate ProgramInvesting GlossaryOfficial ContactsTrust, Compliance and SecurityFrequently Asked Questions

Terms & ConditionsPrivacy Policy
EnglishEnglish

Owned by Daba Markets Inc. By using this site, you accept our Terms and Conditions and Privacy Policy. © 2024 All rights reserved. 2025 All rights reserved